Cleveland Clinic researchers are presenting updated findings from their study of a vaccine aimed at preventing triple-negative breast cancer. The vaccine was well-tolerated and produced an immune response in most patients. The ongoing clinical trial, funded by the U.S. Department of Defense, is evaluating safety and immune response. Anixa Biosciences, Inc. is partnering on the study, which includes patients with early-stage triple-negative breast cancer and those at high risk for recurrence or developing breast cancer. The vaccine targets a lactation protein found in most triple-negative breast cancers. The goal is to develop a preventive vaccine for this aggressive form of the disease, which lacks effective treatments.
Source link
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine
